Pro-Pharmaceuticals, Inc. has retained Camargo Pharmaceutical Services to provide strategic regulatory support for the company’s 505(b)(2) submissions for Davanat with the FDA. Camargo’s regulatory support includes the preparation and submission of NDAs, aNDAs, and 505(b)(2) NDAs to help expedite the regulatory submission and approval process for clients. “Our goal is to get Davanat to market in a timely manner with multiple chemotherapy drugs,” stated David Platt, Ph.D., chief ...